Kazia

KZIA NASDAQ
2.348
-0.061
-2.51%
Closed 16:00 06/21 EDT
Open
2.240
Prev Close
2.409
High
2.400
Low
2.240
Volume
1.55K
Avg Vol (3M)
3.31K
52 Week High
4.270
52 Week Low
2.040
% Turnover
0.03%
Market Cap
14.60M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Kazia KZIA stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Kazia Therapeutics Limited, formerly Novogen Limited, is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. It has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications. The Company's product candidates include Cantrixil (TRX-E-002-1), Anisina (ATM-3507) and Trilexium (TRX-E-009-1). The Company's target indication for Cantrixil is ovarian cancer, and Diffuse Intrinsic Pontine Glioma (DIPG) for Trilexium. The initial target pediatric indication for Anisina is neuroblastoma. Cantrixil is the lead development candidate arising from its SBP technology. Anisina is an approach to chemotherapy that targets the cancer cells' actin cytoskeleton. Trilexium (TRX-E-009-1) is its second lead SBP drug candidate.
MORE >

Recently

Name
Price
%Change